COMBINATION OF NAB-PACLITAXEL WITH TRASTUZUMAB AS NEOADJUVANT CHEMOTHERAPY FOR HER2-POSITIVE BREAST CANCER PATIENTS: EXPERIENCE FROM A SINGLE CENTER
- At: 2015 FIP Congress in Düsseldorf (Germany)
- Type: Poster
- By: LI, Tingting (Guangdong General Hospital; Sun Yat-sen University, Department of Pharmacy, Guangzhou, China)
- Co-author(s): Tingting Li
Anthracycline-based neoadjuvant regimens are widely used for human epidermal growth factor receptor 2 (Her2)-positive breast cancer, which can lead to cardiac toxicity. In order to minimize this side effect, researchers begin to explore the anthracycline-free regimens. Attention was paid to the taxane-based ones.
From July 2009 to June 2014,.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.